GSK
GlaxoSmithKline PLC
49.50$
-1.8%
vs. previous close
Closing price · As of: Aug 14, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.5% | 10.7% | 23.3% | 22.9% | 27.3% | 23.8% | 34.7% | 32.2% | 25.2% | 26.0% | 20.9% | 21.9% | |
| 8.8% | 7.8% | 6.7% | 9.9% | 5.7% | 8.9% | 2.6% | 10.2% | 7.8% | 9.4% | 8.1% | 11.3% | |
| 1.4% | 1.5% | 1.1% | 1.1% | 1.2% | 1.1% | 1.6% | 1.5% | 1.2% | 1.0% | 1.1% | 1.1% | |
| 1.2% | -392.4% | 0.6% | 13.7% | 10.3% | 2.0% | 1.6% | 0.4% | -28.4% | – | – | – | |
| 2.5% | 6.8% | 0.9% | -2.2% | -1.2% | 1.6% | 0.5% | -1.9% | 0.9% | -3.5% | 6.7% | -1.9% | |
| 7.6% | 7.9% | 8.4% | 7.3% | 5.8% | 6.4% | 9.2% | 11.9% | 7.7% | 5.4% | 9.5% | 4.0% | |
| -4.7% | 25.2% | -4.6% | -4.8% | -5.0% | -15.9% | 8.9% | -7.2% | -29.9% | -7.9% | -3.9% | -17.5% | |
| 16.7% | 16.2% | 17.4% | 12.9% | 12.7% | 11.7% | 16.3% | 16.2% | 11.8% | 9.2% | 7.8% | 7.7% | |
| -1.4% | -0.4% | -0.3% | -0.2% | 28.5% | 30.5% | 4.1% | -6.7% | 0.1% | -0.6% | 0.1% | -4.2% | |
| 1.0% | -104.4% | 0.5% | -3.3% | 26.4% | 10.4% | -17.4% | -8.9% | -16.5% | -7.8% | -3.7% | 4.6% | |
| -23.4% | -29.7% | -22.9% | -21.1% | -20.7% | -5.5% | -41.6% | -30.7% | 2.8% | -20.0% | -15.1% | -4.9% | |
| -5.2% | 6.1% | -3.2% | -3.3% | 1.6% | 2.2% | 1.8% | -5.8% | -1.3% | -2.4% | 1.7% | -0.6% | |
| 14.9% | 2.8% | 14.9% | 15.6% | 21.5% | 17.4% | 25.5% | 20.3% | 17.5% | 20.6% | 11.4% | 17.8% |
Data as of: August 14, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.